While waiting for the introduction of novel, active cytotoxic agents to the clinic, it behoves us to utilise currently available anti-neoplastic drugs as best we can. This implies that we continue to extend knowledge of the drug's clinical and cellular pharmacology and optimise drug delivery in terms of dose, route of administration, schedule, combination with other agents, and circadian ordered timing of administration. The addition of folinic acid (leucovorin, etc.) to 5-fluorouracil is one such area where knowledge of the drugs mechanism has led to proposals for its more effective use in the clinic.
In essence, 5-Fu is metabolised to 5-dUMP which binds to and inhibits the enzyme thymidylate synthetase (Figure 1 ). The ability of 5-dUMP to inhibit the enzyme is enhanced by the presence of 5,10-CH2-FH4 which can by synthesised from FA, and stabilises the formation of a covalent, ternary complex of F-dUMP with thymidylate synthetase (Figure 1 ).
There are extensive preclinical data, both in vitro and in vivo (Houghton et al., 1982) suggesting that the combination of 5-Fu/FA is significantly more efficacious than 5-Fu alone. In order to provide guidelines for clinical usage, in vitro studies have been used to define minimum effective concentrations and durations of exposure to FA required to maximise the cytotoxicity of 5-Fu. For example, the lowest concentration of FA that provided maximum potentiation was 10YM for mouse sarcoma 180 cells treated with 5-Fu at a concentration of 30 lLM for 3 h. This implies that attempts should be made to achieve plasma FA concentrations of at least 10 JAM and maintain these for at least 3 h (Evans et al., 1981) . This type of approach may seem naive, in view of the complex intracellular metabolism which both drugs must undergo to be 'activated' and as plasma drug concentrations at best given an indirect estimate of drug concentration at its molecular target. Nevertheless, this allows us to use the clinical pharmacokinetic parameters for FA to calculate dose regimens which will achieve 'ball-park' plasma exposures compared to those considered active in vitro, and must serve as a more scientific method of deriving dose schedules than empiricism.
There has been a large number of phase I/II studies of 5-Fu in combination with FA using a range of dose schedules (for both drugs 5-Fu containing regimens, generally indicate a range of useful activity for 5-Fu/FA. Doroshow et al. (1989) have shown that 5-Fu (bolus 370 mg m-2 day-' on days 1 -5) and high dose folinic acid infusion (500 mg m-2 day-' on days 1-6) is a useful salvage therapy in patients with refractory metastatic breast cancer. Sixty patients, who had been previously treated with 5-Fu containing regimens, were treated with 5-Fu/FA and I CR (duration 8.7 months) and 9 PRs (median duration 3.2 months) were seen (objective response, 17%, 95% confidence intervals for response, 8-27%).
There is limited evidence suggesting that 5-Fu/FA is active in locally advanced squamous carcinoma of the head and neck, but it has already been incorporated into complex split chemotherapy/radiotherapy regimens for this disease (Wendt et al., 1989) .
The most mature data, in terms of phase III trials, have been accrued for threatment of patients with advanced colorectal carcinoma. An update of current results from seven randomised trials comparing 5-Fu/FA against single agent 5-Fu was presented recently by O'Connell (1989) Dose limiting toxicity of the 5-Fu/FA combination depends on the schedule. It tends to be severe diarrhoea for weekly administration and mylosuppression, and stomatitis for the 5 x daily loading course. Certainly in the Mayo Clinic/NCCTG experience, stomatitis was worse in the combination arm, diarrhoea was mild and evenly distributed and myelosuppression was more marked with 5-Fu alone. A quality of life assessment indicated that 5-Fu plus low dose FA was the preferred treatment.
Is this treatment cost effective? According to our current hospital pharmacy prices, a 6-week course of 5-Fu/FA according to the Roswell Park Memorial Schedule would cost approximately £540.00 compared to £15.00 for 5-Fu. However, response rates and survival were similar in the Mayo Clinic/NCCGT study comparing two different FA schedules (200 mg m-2 day-' on days 1-5 versus 20 mg m-2 day-' on days 1-5) and therefore one would conclude from this trial that 5-Fu/low dose FA was the preferred arm in terms of cost effectiveness.
Is it possible to refine combination treatment with 5-Fu/ FA further? The notion of having a specific, measurable biochemical target (the ternary complex with thymidylate synthetase) for 5-Fu/FA implies an ability to titrate drug dose schedules almost to an individual level, if there are correlates between response and tissue biochemical parameters. Investigators at the NCI and Mayo Clinic are attempting, prospectively, to estimate the kinetics of formation of the thymidylate synthetase-F-dUMP complex using a radioimmuno assay in sequential breast cancer biopsies following treatment with 5-Fu/FA, and relate this to response. This is a fascinating study and obviously, potentially gives much more information than measuring plasma drug concentrations.
In terms of 5-Fu delivery, there is increasing evidence to suggest that prolonged, continuous infusions of 5-Fu yield higher response rates in metastatic colorectal cancer than conventional bolus (weekly or loading) administration. Lokich et al. (1989) have recently reported that continuous infusion of 5-Fu, 300mgm-2day-1 for 10 weeks had a significantly higher response rate than bolus 5-Fu, 500mgm 2day ' on days 1-5 (30% vs 7%). It may be that prolonged exposure to 5-Fu leads to stabilisation or a greater degree of inhibition of thymidylate synthetase than generating high intracellular drug concentration for brief periods following bolus administration (5-Fu has a plasma half-life of approximately 10 min). Obviously, there may be a potential to combine prolonged infusions of 5-Fu with FA. This is an interesting field, and we all like to see 'old drugs learn new tricks', but it is important to remember that the survival benefits of combined treatment, when conferred, are, thus far, relatively minor and this treatment combination should remain the subject of further research rather then routine clinical application.
